Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Vidence, LLC, launched on June 18, 2020, aims to enhance cancer treatment through its SCIMON platform, which integrates clinical and genomic data. This oncology informatics company helps researchers and healthcare providers accelerate cancer treatment innovations. Notably, Vidence collaborates with Bristol Myers Squibb (NYSE: BMY) to analyze treatment patterns and outcomes from a large dataset of over 100,000 patients. The collaboration seeks to improve patient care and outcomes in oncology by utilizing a comprehensive knowledge base.